Home > Insider Trading > Filing (0001209191-22-003197)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1868734	Cincor Pharma Inc.	CINC	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1680194	Sofinnova Management X, L.l.c.	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1680200	Sofinnova Venture Partners X, L.p.	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1720685	Maha Katabi	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-11	5,248,949	$0.00	5,248,949	No	4	C	Indirect	By Sofinnova Venture Partners X, L.P.
Common Stock	Acquisiton	2022-01-11	325,000	$16.00	5,573,949	No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2022-01-11	13,571,428	$0.00	3,991,596	$0.00
Common Stock	Series B Preferred Stock	Disposition	2022-01-11	4,275,000	$0.00	1,257,353	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports.